Should You Buy GlaxoSmithKline plc, AstraZeneca plc & Hargreaves Lansdown plc Ahead Of The Results This Week?

Dave Sullivan digs deeper into prospects for GlaxoSmithKline plc (LON: GSK), AstraZeneca plc (LON: AZN) and Hargreaves Lansdown plc (LON: HL) ahead of their results this week.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

I don’t know about you, but I for one am glad to see the back of January. Despite my personal portfolio’s small-cap growth-oriented construction, I’ve been along for the ride on the turbulent market roller coaster.

That said, the volatility has, in my opinion opened some interesting opportunities. However, as we head into February investors will be updated with both interim and preliminary results from a lot of companies, which could well impact on the share price in either direction.

A quick glance at the 12-month chart shows all three shares under review comfortably outperforming the FTSE 100.

But once we close that chart to a month view, a slightly different picture emerges with only one company, GlaxoSmithKline (LSE: GSK) outperforming the blue-chip index.

Defying the bears?

I’ve been watching shares in pharma giant GlaxoSmithKline for a while now. As I’ve written before, I’ve been conscious of the level of dividend cover falling to less than 1 for the year to December 2015.

However, the market has been marking the shares higher of late, perhaps due to their perceived safe-haven appeal, perhaps due to the possibility that investors are beginning to believe the company’s prospects will improve as its business is reshaped following the deal with Novartis.

Currently, I’m still cautious and will wait for the results as analysts have been marking down their EPS estimates over the last one-month and three-months, albeit by only 1 penny per share, according to data from Stockopedia.

Back on the up?

On the other side of the coin, or brokers’ forecasts to be more precise, we’ve seen earnings estimates rise by around $22m at sector peer Astrazeneca (LSE: AZN). This puts the shares on a 12-month rolling forecast P/E of just under 16 times and the shares are set to yield in excess of 4%.

In addition, it’s pleasing to see that the level of dividend cover is beginning to rise too, with dividend cover expected to increase to 1.55 times for the year ending December 2015 – much safer than the less-than-one-times cover for the previous financial year.

As we can see, the shares have more or less tracked the index over the last month, which leaves me thinking that they’re in need of a catalyst to get them moving in the right direction. Whether this will arrive with the full-year results is yet to be seen.

Paying up for quality?

It’s hard to argue with the returns over the last 12 months delivered to shareholders in investment management firm Hargreaves Lansdown (LSE: HL). The shares have significantly outperformed the index and rightly so in my view.

As I’ve written before, it’s rare to see such quality in a mature blue-chip company. Indeed it’s the quality on offer here that you could argue justifies the eye-watering 32 times forecast earnings price tag that the shares attract.

Despite the quality here, investors may well see the shares hit by the postponement of the Lloyds Banking Group public share sale that was specifically mentioned by CEO Ian Gorham when the company updated the market back in October 2015. Indeed, broker forecasts have been sliding for some time now, and there’s room for some further downgrades should the market fall further. Despite this, the dividend is expected to grow again this year, giving a forecast yield of just under 3%

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Dave Sullivan has no position in any shares mentioned. The Motley Fool UK has recommended AstraZeneca, GlaxoSmithKline, and Hargreaves Lansdown. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »

Investing Articles

Are HSBC shares a FTSE bargain? Here’s what the charts say!

There are plenty of dirt-cheap FTSE 100 banking stocks for investors to choose from today. Our writer Royston Wild believes…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Just released: Share Advisor’s latest ‘Hold’ recommendation [PREMIUM PICKS]

In our Share Advisor newsletter service, we provide buy, sell, and hold guidance for our universe of recommendations.

Read more »

Investing Articles

Investing £5 a day could help me build a second income of £329 a month!

This Fool explains how £5 a day, or one less takeaway coffee, could help her build a monthly second income…

Read more »